Clinical Trials Search
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
The purpose of this study is to test any good and bad effects of this combination of drugs - cediranib and olaparib. Researchers hope to learn if this combination of the drugs will shrink the cancer by at least one-quarter compared to its present size. Cediranib is an experimental drug. Olaparib has already been FDA-approved to treat patients with advanced ovarian cancer.
Primary Objectives To determine the objective response rate (ORR) of cediranib plus olaparib in combination in patients with advanced or metastatic solid tumors of the following tumor types: non-small cell lung cancer (NSCLC), germline BRCA1/2wt, basaloid triple negative breast cancer (b-TNBC), pancreatic ductal adenocarcinoma (PDAC), and small cell lung cancer (SCLC). The responses will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary Objectives To assess the safety and tolerability of oral administration of cediranib in combination with olaparib in patients with select advanced solid tumors.
AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)